At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 17 enrolled
Drug / intervention
Bazedoxifene/Conjugated Estrogens (BZA/CE) +1 moredrug
Likely dose
Bazedoxifene/Conjugated Estrogens (BZA/CE) 0.45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)
In Brief
A Phase 4 clinical trial evaluating Bazedoxifene/Conjugated Estrogens (BZA/CE) and Placebo Oral Tablet for Obesity and 2 related conditions. Completed, enrolled 17 participants across 1 site.
Detailed Summary
The goal of this pilot clinical study is to perform a randomized placebo-controlled study to assess the beneficial effect of a 3 month-treatment with Bazedoxifene/Conjugated Estrogens (BZA/CE) vs. placebo on glucose homeostasis and body composition in 20 post-menopausal women. The recruitment will be performed at Tulane Health Sciences Center.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Glucose Homeostasis, Postmenopausal Symptoms
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartDec 2014
Primary CompletionApr 2018
TodayJul 2026
First PostedSep 11, 2014
Enrollment StartDec 1, 2014
Primary CompletionApr 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.8 years ago
Interventions
Bazedoxifene/Conjugated Estrogens (BZA/CE)drug
Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
Placebo Oral Tabletdrug
Daily placebo tablet